Latigo Biotherapeutics outlined plans for an IPO as it prepares late-stage studies for its oral Nav1.8 inhibitor LTG-001 in a bid to compete in non-opioid pain. In IPO-related disclosures, Latigo said it intends to initiate a placebo-controlled Phase 3 trial in participants undergoing bunionectomy and an additional open-label Phase 3 safety trial across a broader mix of post-surgical and non-surgical acute pain settings, with topline results expected in the second half of 2027. The company also advances LTG-321 for osteoarthritis, with Phase 2 readouts due in the same half of 2027. Latigo’s pipeline is designed around peripheral sodium channel inhibition, targeting Nav1.8, which has already been validated by Vertex’s FDA-approved Journavx (suzetrigine). The IPO documents also set out progress, including funding accumulated since 2018 and an earlier Phase 2 completion for LTG-001. Separately, Scribe Therapeutics filed for a Nasdaq IPO to fund initial clinical development of RNA-interference style lipid-lowering genetics programs. Scribe’s planned public raise targets a Phase 1 study of STX-1150, a PCSK9 silencing candidate, plus clinical execution for APOC3 and LPA targeting assets, with early topline expectations set for later 2027.